anti-PD-1-hIL2 (Teva Pharmaceuticals/Tel Aviv University)

N/A

Report date: 2025/06/11 10:45:48

Base Information

Drug Nameanti-PD-1-hIL2 (Teva Pharmaceuticals/Tel Aviv University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 modulatorsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptorProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTel Aviv University
China Registration ClassN/A

Develop Information

Active CompaniesTel Aviv UniversityTeva Pharmaceutical Industries Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A